Possible renoprotective effects of dabigatran

References (5)

1. Altın C, Sakallıoğlu O, Gezmiş E, Müderrisoğlu H. A novel oral anticoagulant, dabigatran, in acute renal infarction. Anatol J Cardiol 2015
2. [CrossRef] 2. Demirtaş S, Karahan O, Yazıcı S, Güçlü O, Çalışkan A, Tezcan O, et a. Investigation of possible prophylactic,renoprotective, and cardioprotective effects of thromboprophylactic drugs against ischemia-reperfusion injury. Kaohsiung J Med Sci 2015
3. [CrossRef] 3. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011
4. [CrossRef] 4. Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, et al. American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011
5. [CrossRef] 5. Yazıcı S, Karahan O, Oral MK, Bayramoğlu Z, Ünal M, Çaynak B, et al. Comparison of renoprotective effect of dabigatran with low-molecularweight heparin. Clin Appl Thromb Hemost 2015. [CrossRef]